Role of endothelin receptor subtype B (ET-B) in myocardial ischemia. 1994

C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
Bristol-Myers Squibb, Princeton, NJ 08543.

Previous work indicated that endothelin (ET) may be involved in the pathogenesis of myocardial ischemia, although the relative importance of the ET receptor subtypes is presently not clear. The purpose of this study was to determine the role of myocardial ET-B receptors in mediating ischemic/reperfusion damage in isolated rat hearts. Saturation binding analyses were conducted with [125I]ET-1 and [125I]IRL-1620 to assess changes in ET-A and ET-B receptor binding. Total ET receptor density (Bmax) was greater in atrial versus ventricular tissue. ET-A Bmax was 8 to 10-fold greater than ET-B Bmax. In ischemic and ischemic/reperfused atrial tissue neither the equilibrium dissociation constant (Kd) nor Bmax for ET-B receptors was changed. The ET-B receptor Kd in ischemic or ischemic/reperfused ventricular tissue was also unchanged. In ischemic ventricular tissue there was a trend towards an increased ET-B Bmax, which was accentuated after ischemia/reperfusion. No changes were found in ET-A Bmax or Kd in ischemic ventricular or atrial tissue. The physiological importance of this receptor subtype in ischemic myocardium was determined using the selective ET-B agonist, sarafotoxin S6c. In non-ischemic tissue no effect on coronary flow or function were observed with sarafotoxin S6c. Furthermore, no changes were seen in ischemic time to contracture or any of the reperfusion indexes of myocardial damage. The sarafotoxin S6c utilized was active as it inhibited [125I]ET-3 binding to ET-B receptors (Ki = 0.1 nM). Thus, the pro-ischemic effect of ET-1 seems to be mediated by ET-A receptors. ET-B receptors do not appear to play a role in the pathogenesis of myocardial ischemia.

UI MeSH Term Description Entries
D008297 Male Males
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014757 Viper Venoms Venoms from SNAKES of the viperid family. They tend to be less toxic than elapid or hydrophid venoms and act mainly on the vascular system, interfering with coagulation and capillary membrane integrity and are highly cytotoxic. They contain large amounts of several enzymes, other factors, and some toxins. Russell Viper Venom,Russell Viper Venoms,Russell's Viper Venom,Russell's Viper Venoms,Viperidae Venoms,Cerastes Venom,Cerastes Venoms,Egyptian Sand Viper Venom,Viper Venom,Viperotoxin,Russells Viper Venom,Russells Viper Venoms,Venom, Cerastes,Venom, Russell Viper,Venom, Russell's Viper,Venom, Viper,Venoms, Cerastes,Venoms, Russell Viper,Venoms, Russell's Viper,Venoms, Viper,Venoms, Viperidae,Viper Venom, Russell,Viper Venom, Russell's,Viper Venoms, Russell,Viper Venoms, Russell's
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D016232 Endothelins 21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides. Endothelium-Derived Vasoconstrictor Factors,Endothelin,Vasoconstrictor Factors, Endothelium-Derived
D017202 Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION). Heart Disease, Ischemic,Ischemia, Myocardial,Ischemic Heart Disease,Disease, Ischemic Heart,Diseases, Ischemic Heart,Heart Diseases, Ischemic,Ischemias, Myocardial,Ischemic Heart Diseases,Myocardial Ischemias
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017466 Receptors, Endothelin Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells. Endothelin Receptors,Receptors, Endothelium-Derived Vasoconstrictor Factor,Endothelin Receptor,Endothelium Derived Vasoconstrictor Factor Receptors,Receptors, Endothelins,Receptor, Endothelin,Receptors, Endothelium Derived Vasoconstrictor Factor
D044023 Receptor, Endothelin B A subtype of endothelin receptor found predominantly in the KIDNEY. It may play a role in reducing systemic ENDOTHELIN levels. Endothelin B Receptors,Endothelin B-2 Receptor,Receptor, Endothelin B, Type 2,Endothelin B-2 Receptors,Endothelin B 2 Receptor,Endothelin B 2 Receptors,Endothelin B Receptor,Receptor, Endothelin B-2,Receptors, Endothelin B,Receptors, Endothelin B-2

Related Publications

C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
January 1999, Physiological research,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
January 1998, Brain research bulletin,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
January 2000, Urologia internationalis,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
December 1999, European journal of pharmacology,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
March 1995, The Journal of biological chemistry,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
September 2002, Stroke,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
January 2000, Shock (Augusta, Ga.),
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
January 1998, Journal of cardiovascular pharmacology,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
June 2001, Journal of hepatology,
C A Sargent, and E C Liu, and C C Chao, and H Monshizadegan, and M L Webb, and G J Grover
June 1995, Protein expression and purification,
Copied contents to your clipboard!